GlassScriptPhysician profile
Moishia Mcelroy
NPI 1659832368
$3,299.67
in general payments reported to CMS, 2019-2025
41 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $859 · 2023: $725 · 2024: $989 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.57 |
| Education | $193.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $336.79 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $284.07 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $242.23 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $221.85 | 2022-2024 | Enhertu, Calquence |
| Genzyme Corporation | $177.64 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $159.80 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Seagen INC. | $154.92 | 2022-2023 | Adcetris |
| Karyopharm Therapeutics INC. | $153.67 | 2022-2023 | Xpovio |
| Genentech, INC. | $145.75 | 2024 | |
| Janssen Biotech, INC. | $97.79 | 2022-2025 | Rybrevant, Imbruvica |
| Merck Sharp & Dohme LLC | $90.74 | 2023-2024 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $81.18 | 2023-2025 | |
| Pfizer INC. | $80.85 | 2024-2025 | |
| Sobi, INC | $77.35 | 2022-2023 | |
| Deciphera Pharmaceuticals INC. | $75.76 | 2022-2024 | Qinlock, Tgct |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75.22 | 2025 | |
| Incyte Corporation | $74.81 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| Sumitomo Pharma America, INC. | $71.15 | 2023-2025 | Orgovyx |
| Scynexis, INC. | $70.69 | 2022 | |
| Daiichi Sankyo INC. | $50.52 | 2022-2024 | Enhertu |
| Celgene Corporation | $50.22 | 2023-2025 | Reblozyl, Pomalyst |
| Alnylam Pharmaceuticals INC. | $47.00 | 2023-2024 | Givlaari |
| Lilly USA, LLC | $44.97 | 2023-2025 | Verzenio, Jaypirca |
| Taiho Oncology, INC. | $44.04 | 2024 | |
| Gilead Sciences, INC. | $35.89 | 2024 | |
| Genentech USA, INC. | $35.22 | 2023-2024 | Phesgo, Tecentriq Hybreza, Tecentriq |
| Pharmaessentia USA Corporation | $31.66 | 2024 | Besremi |
| Glaxosmithkline, LLC. | $28.45 | 2025 | Ojjaara, Blenrep |
| Tersera Therapeutics LLC | $27.61 | 2023 | Zoladex |
| Morphosys, US INC. | $27.10 | 2022 | |
| Amgen INC. | $23.10 | 2022 | |
| Emd Serono, INC. | $20.83 | 2024 | |
| Mylan Institutional INC. | $19.45 | 2023 | Fulphila, Ogivri |
| Blueprint Medicines Corporation | $19.39 | 2022 | |
| Syndax Pharmaceuticals, INC. | $18.94 | 2025 | |
| Kyowa Kirin, INC. | $18.75 | 2022 | |
| Cti Biopharma Corp. | $18.53 | 2022 | |
| Aveo Pharmaceuticals, INC. | $17.74 | 2022 | |
| Stemline Therapeutics INC. | $17.16 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $15.98 | 2024 | |
| Array Biopharma INC | $14.86 | 2024 | Lorbrena, Mektovi, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moishia Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.